ESR1 and breast carcinoma: NAC is increasingly used in breast cancer therapy, and clinic-pathological subtypes, such as estrogen receptor positive (ER), progesterone receptor positive (PR), and human epidermal growth factor receptor 2 positive (HER-2), can provide prognostic information regarding the risk of local regional recurrence after NAC.